Screener
Sarepta Therapeutics, Inc. SRPT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|
| Purchase of property and equipment | (2,636) | (75,447) |
| Purchase of intangible assets | (1,000) | (2,000) |
| Acquisition of strategic investment | — | (245,819) |
| Net cash used in investing activities | (227,762) | (258,966) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program | 241 | 17,181 |
| Proceeds from borrowings under the Revolving Credit Facility | 425,000 | — |
| Repayments of borrowings under the Revolving Credit Facility | (425,000) | — |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s investing cash flow?
- Sarepta Therapeutics, Inc. (SRPT) reported investing cash flow of -$93.37M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Sarepta Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude